Finance entity
All 1 tracked stories fall under one category: earnings. NeurAxis, Inc. is most often covered alongside Raj Pruthi, which appears in 1 of these 1 story. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. NeurAxis, Inc. is most often covered alongside Raj Pruthi, which appears in 1 of these 1 story. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.5 in the same window. NeurAxis, Inc. appears in 1 tracked Finance story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 72 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NeurAxis, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting critical pivots in clinical development and commercial execution. Relmada remains focused on its Phase 3 REL-1017 program for depression, while NeurAxis reports steady growth in its neuromodulation therapy for pediatric patients.
NeurAxis, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
